The pharmacology of paediatric incontinence

BJU International

Volumn 86, Issue 5, 2000, Pages 581-589

  Hoebeke, P B ^a   Vande Walle, J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ATROPINE; BACLOFEN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETHANECHOL; CALCIUM ANTAGONIST; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; EPHEDRINE; FLAVOXATE; GLYCOPYRRONIUM BROMIDE; HYOSCYAMINE; IMIPRAMINE; ISOPROPAMIDE IODIDE; METHYL BROMIDE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NOREPHEDRINE; OCTATROPINE METHYLBROMIDE; OXYBUTYNIN; PHENOXYBENZAMINE; PHENYLPROPANOLAMINE; PHYSOSTIGMINE; PROPANTHELINE BROMIDE; PSEUDOEPHEDRINE; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADULT; BLADDER MUSCLE; BLADDER SPHINCTER; CENTRAL NERVOUS SYSTEM; CHILD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED DISEASE; HUMAN; INCONTINENCE; PRIORITY JOURNAL; REVIEW; URINE INCONTINENCE;

AFFERENT PATHWAYS; CENTRAL NERVOUS SYSTEM; CHILD; EFFERENT PATHWAYS; HUMANS; MUSCLE, SMOOTH; PERIPHERAL NERVOUS SYSTEM; URETHRA; URINARY BLADDER; URINARY INCONTINENCE;

EID: 0033823114     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00833.x     Document Type: Review

References (39)

1. Tanagho EA, Meyers FH. The 'internal sphincter': is it under sympathetic control? Invest Urol 1969; 7: 79-89
2. Wein A. Pharmacology of incontinence. Urol Clin North Am 1995: 22: 557-77
3. de Groat WC. Anatomy and physiology of the lower urinary tract. Urol Clin North Am 1993; 20: 383-401
4. Elbadawi A, Schenk EA. Dual innervation of the mammalian urinary bladder: a histochemical study of the distributions of cholinergic and adrenergic nerves. Am J Anat 1966; 119: 405-27
5. Lepor H, Gup D, Shapiro E, Baumann M. Muscarinic cholinergic receptors in normal and neurogenic human bladder. J Urol 1987; 137: 782
6. Krane RJ, Olsson C. Phenoxybenzamine in neurogenic bladder dysfunction: a theory of micturition. J Urol 1973; 110: 650-2
7. Nordling J. Influence of the sympathetic nervous system on lower urinary tract in man. Neurourol Urodynam 1989; 2: 3
8. Norlen L, Sundin T, Waagstein F. Beta adrenoceptor stimulation of the human urinary bladder in vivo. Acta Pharmacol Toxicol 1978; 43: 26-30
9. Kaplan PE, Nanninga JB. Augmentation of bladder contractility after beta-adrenergic blockade in spinal cord injured patients. Acta Neural Scand 1980; 61: 125-30
10. Jensen D. Pharmacological studies of uninhibited neurogenic bladders. II. The influence of cholinergic excitatory and inhibitory drugs on the cystometrogram of neurological patients with normal and uninhibited neurogenic bladder. Acta Neural Scand 1981; 64: 175-95
11. Tanagho EA, Schmidt RA, Gomes de Araujo C. Urinary striated sphincter: what is its nerve supply? Urology 1982; 20:415-7
12. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Ural 1982; 128: 492-7
13. Fredericks CM, Anderson GF, Kreulen DL. A study of the anticholinergic and antispasmodic activity of oxybutynin on rabbit detrusor. Invest Urol 1975; 12: 317-9
14. Malmgren A, Andersson KE, Fovaeus M, Sjögren C. Effects of cromakalim and pinacidil on normal and hypertrophied rat detrusor in vitro. J Urol 1990; 143: 828-34
15. Sant G. Intravesical 50% dimethylsulfoxide in the treatment of interstitial cystitis. Urology 1985; 4 (Suppl): 17
16. Brendler CR, Radebaugh LC, Mohler JL. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989: 141: 1350-2
17. Painter KA, Vates TS, Bukowski TP et al. Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia. J Urol 1996; 156: 1459-62
18. Smellie JM, McCrigor VS, Meadow SR, Rose SJ, Douglas MF. Nocturnal enuresis: a placebo controlled trial of two antidepressant drugs. Arch Dis Child 1996; 75: 62-6
19. Wallace IR, Forsythe WI. The treatment of enuresis: a placebo controlled clinical trial of propantheline, propantheline and phenobarbitone and a placebo. Br J Clin Pract 1969; 23: 207-10
20. Montanari G, Baraldo M, Zara G, Benetello P, Secchieri S, Furnalut M. Side effects of imipramine therapy in enuretic children. Pharmacol Res 1990: 22 (Suppl 3): 3
21. Foxman B, Burciaga Valdez R, Brook RH. Childhood enuresis: prevalence, perceived impact and prescribed treatments. Pediatrics 1986; 77: 482-7
22. Miller K, Atkin B, Moody ML. Drug therapy for nocturnal enuresis. Current treatment recommendations. Drugs 1992; 44: 47-56
23. Jorgensen DD, Lober M, Christiansen J, Gram LF. Plasma concentration and clinical effect in imipramine treatment of childhood enuresis. Clin Pharmacokinetics 1980; 5: 386-93
24. Levering JS, Tallett SE, McKendry JBJ. Oxybutynin efficacy in the treatment of primary enuresis. Pediatrics 1988; 82: 104-6
25. Al-Waili NS. Indomethacin suppository to treat primary nocturnal enuresis: double blind study. J Urol 1989: 142: 1290-2
26. Metin A, Aykol N. Diclofenac sodium suppository in the treatment of primary nocturnal enuresis. M Urol Nephrol 1992; 24: 113-7
27. Diokno AC. Lapides J. Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 1972: 108: 307-9
28. Aubert D, Cencig R, Royer M. Le traitement par le chlorhydrate d' oxybutynine des incontinences urinaires de 1' enfant et des états d'hyperactivité vésicale. Ann Pédiatr (Paris) 1986; 33: 629-34
29. Scholtmeijer RJ. van Mastrigt R. The effect of oxyphenonium bromide and oxybutynin hydrochloride on detrusor contractility and reflux in children with vesicoureteral reflux and detrusor instability. J Urol 1991; 146: 660-2
30. Hjälmas K, Hellström AL, Mogren K et al. Safety, efficacy and pharmacokinetics of tolterodine in paediatric patients with overactive bladder. Invited lecture of 2nd Congress of the ICCS, Denver August, 1999
31. Smey R, Firlit CF, King LR. Voiding pattern abnormalities in normal children: results of pharmacologie manipulation. J Urol 1978: 120: 574-7
32. Hilwa GM. Perlmutter A. The role of adjunctive drug therapy for intermittent catheterization and self catheter-ization in children with vesical dysfunction. J Urol 1978; 119: 551-4
33. Joseph DB, Bauer SB, Colodny AH et al. Clean intermittent catheterisation of infants with neurogenic bladder. Pediatrics 1989: 84: 78-82
34. Baskin LS. Kogan BA. Benard E. Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterization. Br J Urol 1990: 66: 532-4
35. Dahlstrom A. The adrenergic innervation of the urinary bladder in the cat and man in the normal state and after parasympathetic denervation. Acta Pharmacol Toxicol 1978; 4: 19-25
36. Jensen D Jr. Altered adrenergic innervation in the uninhibited neurogenic bladder. Scand J Urol Nephrol 1981; 15: 60
37. Jensen D Jr. Uninhibited neurogenic bladder treated with prazosin. Scand J Urol Nephrol 1981; 15: 229-33
38. Bouchot 0, Buzelin JM, Labat JJ. Efficacité àlong terme des médicaments anticholinergiques et alpha-bloquants sur le détrusor d'enfants atteints de myéloméningocèle. J D' Urol 1988: 94: 83-6
39. Amark P. Beck 0. Effect of phenylpropanolamine on incontinence in children with neurogenic bladders. A double-blind crossover study. Acta Paediatr 1992: 81: 345-50